"Gene Targeting into the 21st Century: Mouse Models of Human Disease from Cancer to Neuropsychiatric Disorders."
MARIO R. CAPECCHI was born in Verona, Italy in 1937. He received his B.S. degree in chemistry and physics from Antioch College in 1961 and his Ph.D. degree in biophysics from Harvard University in 1967. His thesis work, under the guidance of Dr. James D. Watson, included the analysis of the mechanisms of nonsense suppression; the initiation of protein synthesis, including the demonstration of Formylmethionine tRNA as the initiator of protein synthesis; and the mechanisms of protein termination. From 1967-69 Dr. Capecchi was a Junior Fellow of the Society of Fellows at Harvard University. In 1969 he became an Assistant Professor in the Department of Biochemistry, Harvard School of Medicine. He was promoted to Associate Professor in 1971. In 1973 he joined the faculty at the University of Utah as a Professor of Biology. Since 1988 Dr. Capecchi has been an investigator of the Howard Hughes Medical Institute; since 1989, a Professor of Human Genetics at the University of Utah School of Medicine; and since 1993, Distinguished Professor of Human Genetics and Biology. He is also co-chairman of the Department of Human Genetics.
Dr. Capecchi is best known for his pioneering work on the development of gene targeting in mouse embryo-derived stem (ES) cells. This technology allows scientists to create mice with mutations in any desired gene. The power of this technology is that the investigator chooses both which gene to mutate and how to mutate it. The investigator has virtually complete freedom on how to manipulate the DNA sequences in the genome of living mice. This allows scientists to evaluate in detail the function of any gene during the development or post-developmental phase of the mouse. His research interests include the molecular genetic analysis of early mouse development, neural development in mammals, production of murine models of human genetic diseases, gene therapy, homologous recombination and programmed genomic rearrangements in the mouse.
Dr. Capecchi is a member of the National Academy of Sciences (1991) and the European Academy of Sciences (2002). He has won numerous awards, including the Bristol-Myers Squibb Award for Distinguished Achievement in Neuroscience Research (1992), the Gairdner Foundation International Award for Achievements in Medical Sciences (1993), the General Motors Corporation’s Alfred P. Sloan Jr. Prize for Outstanding Basic Science Contributions to Cancer Research (1994), the German Molecular Bioanalytics Prize, (1996), the Kyoto Prize in Basic Sciences (1996), the Franklin Medal for Advancing Our Knowledge of the Physical Sciences (1997), the Feodor Lynen Lectureship (1998), the Rosenblatt Prize for Excellence (1998), the Baxter Award for Distinguished Research in the Biomedical Sciences (1998), the Helen Lowe Bamberger Colby and John E. Bamberger Presidential Endowed Chair in the University of Utah Health Sciences Center (1999), lectureship in the Life Sciences for the Collège de France (2000), the Horace Mann Distinguished Alumni Award, Antioch College (2000), the Italian Premio Phoenix-Anni Verdi for Genetics Research Award (2000), the Spanish Jiménez-Diáz Prize (2001), the Pioneers of Progress Award (2001), the Albert Lasker Award for Basic Medical Research (2001), the National Medal of Science (2001), the John Scott Medal Award (2002), the Massry Prize (2002), the Pezcoller Foundation-AACR International Award for Cancer Research (2003), the Wolf Prize in Medicine (2002/03), the March of Dimes Prize in Developmental Biology (2005),and the Nobel Prize in Physiology and Medicine (2007) with Oliver Smithies and Martin Evans.
Research interests include: the molecular genetic analysis of early mouse development, neural development in mammals, production of murine models of human genetic diseases, gene therapy, homologous recombination and programmed genomic rearrangements in the mouse.